upfront 治疗：持续治疗的案例。
Upfront therapy: the case for continuous treatment.
机构信息
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; and The Royal Melbourne Hospital, Parkville, Victoria, Australia.
出版信息
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):55-58. doi: 10.1182/hematology.2021000232.
Abstract
Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.
摘要
BTKi 和 BCL2i 均被认为是 CLL 一线治疗的标准治疗方法。在本文中，我提出了赞成 BTKi 作为初始治疗的理由。基于 Venetoclax 的方案具有治疗时间固定的优势，但具有某些高危特征的患者与无高危特征的患者相比，PFS 可能较差。
相似文献
1
Upfront therapy: the case for continuous treatment.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):55-58. doi: 10.1182/hematology.2021000232.
2
Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
Cancer. 2024 Oct 1;130(19):3237. doi: 10.1002/cncr.35530.
3
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
J Manag Care Spec Pharm. 2024 Oct;30(10):1106-1116. doi: 10.18553/jmcp.2024.24049. Epub 2024 Jul 24.
4
Frontline treatment in CLL: the case for time-limited treatment.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):59-67. doi: 10.1182/hematology.2021000233.
5
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
JCO Oncol Pract. 2024 Aug;20(8):1132-1139. doi: 10.1200/OP.23.00630. Epub 2024 Apr 16.
6
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
Br J Haematol. 2024 Oct;205(4):1395-1403. doi: 10.1111/bjh.19613. Epub 2024 Jul 24.
7
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood. 2020 Jun 18;135(25):2266-2270. doi: 10.1182/blood.2020004782.
8
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):10-17. doi: 10.1182/hematology.2020000168.
9
Is there a role for anti-CD20 antibodies in CLL?
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):68-75. doi: 10.1182/hematology.2021000234.
10
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):216-223. doi: 10.1016/j.clml.2020.10.012. Epub 2020 Oct 29.
引用本文的文献
1
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia.
Cells. 2024 Nov 20;13(22):1922. doi: 10.3390/cells13221922.
2
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Curr Oncol Rep. 2024 Feb;26(2):136-146. doi: 10.1007/s11912-023-01482-6. Epub 2024 Jan 4.
本文引用的文献
1
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma. 2021 Dec;62(13):3278-3282. doi: 10.1080/10428194.2021.1957871. Epub 2021 Aug 13.
2
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.
3
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood. 2021 Sep 9;138(10):836-846. doi: 10.1182/blood.2020009578.
4
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
5
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica. 2021 Sep 1;106(9):2354-2363. doi: 10.3324/haematol.2020.259432.
6
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28.
7
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
8
Ibrutinib for Chronic Lymphocytic Leukemia with Alterations.
N Engl J Med. 2020 Jul 30;383(5):498-500. doi: 10.1056/NEJMc2005943.
9
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
10
Management of Ibrutinib Toxicities: a Practical Guide.
Curr Hematol Malig Rep. 2020 Jun;15(3):177-186. doi: 10.1007/s11899-020-00576-3.
Zotero 插件